Aims and Scope

Current Cancer Reports (CCR) (ISSN: 2661-3166) is an open access, continuously published, international, refereed journal dedicated to publish articles covering all areas of carcinogenesis, prevention, diagnosis, treatment, drug development and related policy.

The journal aims at promoting research communications, and providing a platform for doctors, researchers, physicians, pharmacists and healthcare professionals to find the most recent advances in all areas of cancer-related fields. Current Cancer Reports accepts original research articles, reviews, minireviews, case reports, image data, novel hypothesis and rapid communication covering all respects of carcinogenesis and cancer therapy.

The columns of the journal include, but not limited to:
• Original articles and new techniques in cancer research and therapy
• Quick reports
• Case reports
• Clinicopathologic discussion
• Discussion of clinical case
• Expert views
• Exchange of experience
• Novel hypothesis
• Correspondence
• Publish the original incoming letter
• Academic contending/Debate
• etc.

Vol 4 (2022)

Published: 2022-03-23

-- In Progress --

Abstract views: 121   PDF downloads: 53  

Page 133-138

A case of life threatening acute Nivolumab induced autoimmune haemolytic anaemia

blankpage Abdul Rehman Farooq, Clodagh Keohane, Maeve Crowley, Laura Whelan, Neasa Gallwey, Claire Brady, Seamus O'Reilly

Autoimmune haemolytic anemia is a rare but potentially catastrophic adverse event of im-mune checkpoint inhibitor therapy. We present the case of a gentleman who presented with non-specific symptoms while undergoing adjuvant Nivolumab therapy after potential-ly curative surgery for gastroesophageal cancer. The patient’s haemoglobin deteriorated to 4.7 g/dl with no evidence of bleeding and serologic tests indicative of hemolysis. He re-ceived emergent massive RCC transfusion receiving 9 units of bloods in 1 night, and was commenced on high dose methylprednisolone. During subsequent weeks of inpatient care, the patient continued to received multiple daily red cell transfusions and had a total of 53 RCC transfusions during admission, along with high doses of steroids,4 doses of weekly Rituximab as well as 2 doses of IVIG.While he was discharged on day 38 of admission, he required a slow taper of steroids over 6 months. Immune related hemolytic anemias are a rare corollary of immune check point inhibitors. The cases of immune related AIHA docu-mented in the literature were treated with steroids, Rituximab and IVIG, which are also rec-ommended by guidelines for the treatment of immune related haemolytic anemias.

Abstract views: 391   PDF downloads: 124  

Page 128-132

Breast cancer in women in the Democratic Republic of the Congo: Current state of knowledge

blankpage Stanislas Maseb-A-Mwang Sulu, Olivier Mukuku, Stanislas Okitotsho Wembonyama

Breast cancer (BC) is a major health problem with an increasing trend in prevalence and mortality worldwide. It is the most common of female cancers in the world, and thus ranks first in both developed and developing countries. Current knowledge on the epidemiology and biological aspects of breast cancer in women in the Democratic Republic of the Congo remains insufficient and poorly documented. Given the trend towards urbanization of the Congolese population, it is likely that current data will change in the coming decades, due to a foreseeable change in risk factors for the disease. Therefore, the establishment of a cancer registry is necessary in the Democratic Republic of the Congo (DRC) health system for better epidemiological monitoring of cancer and surveillance data necessary for the development of cancer control policies and their integration into primary health care. Strategies that include building local capacity in terms of human resources, equipment and technology transfer could lead to new concepts and therapies adapted to the Congolese geographical context.

View All Issues
Yuesuo Yang-photo  ISSN: 2661-3166
 Abbreviation: Curr Cancer Rep
 Editor-in-Chief: Prof. Yingyu Cui
 Publishing Frequency: Continuous publication
 Article Processing Charges (APC):
Click  here  for more details
 Publishing Model:
Open Access